WAS
PGNX

Winch Advisory Services’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Winch Advisory Services’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-200
Closed -$2K – 362
2018
Q2 		$2K Buy
+200
New +$1.53K ﹤0.01% 301

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Winch Advisory Services's PGNX Position: Q3 2018 in Review

Winch Advisory Services sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2018, closing a stake of 200 shares — an estimated $2K sold.

Winch Advisory Services first reported a position in PGNX in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 148 funds tracked by Wall St. Rank hold PGNX as of Q3 2018.

  • Winch Advisory Services reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • Winch Advisory Services sold 200 Progenics Pharmaceuticals Inc shares in Q3 2018, an estimated $2K.
  • Winch Advisory Services first reported a position in Progenics Pharmaceuticals Inc in Q2 2018 and held it in 1 quarter.
  • Winch Advisory Services's Progenics Pharmaceuticals Inc position peaked at $2K in Q2 2018.
  • 148 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2018.

Based on Winch Advisory Services's 13F filing for Q3 2018, filed 13 Nov 2018.